Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 2
2000 2
2001 2
2002 1
2003 1
2007 1
2008 4
2009 6
2010 4
2011 5
2012 8
2013 12
2014 16
2015 8
2016 16
2017 27
2018 18
2019 17
2020 22
2021 26
2022 18
2023 13
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenomic Landscape of Hematological Malignancies.
Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, Mustjoki S. Dufva O, et al. Among authors: mustjoki s. Cancer Cell. 2020 Sep 14;38(3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. Epub 2020 Jul 9. Cancer Cell. 2020. PMID: 32649887 Free article.
JAK-STAT core cancer pathway: An integrative cancer interactome analysis.
Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, Valent P, Mustjoki SM, Herling M, Moriggl R, Gunning PT. Erdogan F, et al. Among authors: mustjoki sm. J Cell Mol Med. 2022 Apr;26(7):2049-2062. doi: 10.1111/jcmm.17228. Epub 2022 Mar 1. J Cell Mol Med. 2022. PMID: 35229974 Free PMC article. Review.
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vänttinen I, Nygren P, Klievink J, Bouhlal J, Pölönen P, Zhang Q, Adnan-Awad S, Mancebo-Pérez C, Saad J, Miettinen J, Javarappa KK, Aakko S, Ruokoranta T, Eldfors S, Heinäniemi M, Theilgaard-Mönch K, Wartiovaara-Kautto U, Keränen M, Porkka K, Konopleva M, Wennerberg K, Kontro M, Heckman CA, Mustjoki S. Kuusanmäki H, et al. Among authors: mustjoki s. Blood. 2023 Mar 30;141(13):1610-1625. doi: 10.1182/blood.2021011094. Blood. 2023. PMID: 36508699 Free PMC article.
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells.
Sheffer M, Lowry E, Beelen N, Borah M, Amara SN, Mader CC, Roth JA, Tsherniak A, Freeman SS, Dashevsky O, Gandolfi S, Bender S, Bryan JG, Zhu C, Wang L, Tariq I, Kamath GM, Simoes RM, Dhimolea E, Yu C, Hu Y, Dufva O, Giannakis M, Syrgkanis V, Fraenkel E, Golub T, Romee R, Mustjoki S, Culhane AC, Wieten L, Mitsiades CS. Sheffer M, et al. Among authors: mustjoki s. Nat Genet. 2021 Aug;53(8):1196-1206. doi: 10.1038/s41588-021-00889-w. Epub 2021 Jul 12. Nat Genet. 2021. PMID: 34253920
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, Kuusanmäki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Västrik I, Kivinen K, Saarela J, Räty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, Porkka K. Malani D, et al. Among authors: mustjoki s. Cancer Discov. 2022 Feb;12(2):388-401. doi: 10.1158/2159-8290.CD-21-0410. Epub 2021 Nov 17. Cancer Discov. 2022. PMID: 34789538 Free PMC article.
Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma.
Huuhtanen J, Kasanen H, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, Mustjoki S. Huuhtanen J, et al. Among authors: mustjoki s. J Clin Invest. 2023 Mar 15;133(6):e164809. doi: 10.1172/JCI164809. J Clin Invest. 2023. PMID: 36719749 Free PMC article.
Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, Pölönen P, Hohtari H, Saeed K, Hannunen T, Ellonen P, Steinberger P, Kankainen M, Aittokallio T, Keränen MAI, Korhonen M, Mustjoki S. Dufva O, et al. Among authors: mustjoki s. Blood. 2020 Feb 27;135(9):597-609. doi: 10.1182/blood.2019002121. Blood. 2020. PMID: 31830245 Free PMC article.
STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation.
Masle-Farquhar E, Jackson KJL, Peters TJ, Al-Eryani G, Singh M, Payne KJ, Rao G, Avery DT, Apps G, Kingham J, Jara CJ, Skvortsova K, Swarbrick A, Ma CS, Suan D, Uzel G, Chua I, Leiding JW, Heiskanen K, Preece K, Kainulainen L, O'Sullivan M, Cooper MA, Seppänen MRJ, Mustjoki S, Brothers S, Vogel TP, Brink R, Tangye SG, Reed JH, Goodnow CC. Masle-Farquhar E, et al. Among authors: mustjoki s. Immunity. 2022 Dec 13;55(12):2386-2404.e8. doi: 10.1016/j.immuni.2022.11.001. Epub 2022 Nov 28. Immunity. 2022. PMID: 36446385 Free article.
Somatic mutations in "benign" blood diseases.
Mustjoki S. Mustjoki S. Semin Hematol. 2022 Jul;59(3):121-122. doi: 10.1053/j.seminhematol.2022.08.003. Semin Hematol. 2022. PMID: 36115687 No abstract available.
211 results